Dupilumab for Atopic Dermatitis
Trial Summary
What is the purpose of this trial?
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but you must be on a stable regimen of inhaled corticosteroids, topical steroids, and antihistamines for at least 14 days before starting the study. You cannot use systemic immunosuppressants within 30 days of the first sleep study.
What data supports the effectiveness of the drug Dupilumab for treating atopic dermatitis?
Is dupilumab safe for humans?
Dupilumab is generally considered safe for treating atopic dermatitis, but some patients may experience side effects like eye issues and local skin infections. It has a better safety profile compared to some other treatments, but injection-site reactions and conjunctivitis (eye inflammation) are noted as common side effects.23678
What makes the drug Dupilumab unique for treating atopic dermatitis?
Research Team
Amy Paller
Principal Investigator
Lurie Children's Hospital/Northwestern University
Eligibility Criteria
Children aged 6-17 with moderate to severe atopic dermatitis (AD) that isn't well-controlled by topical treatments can join. They must have a history of sleep disturbances due to AD and be on stable medication regimens. Kids who've used certain meds recently, have other conditions affecting sleep, or cannot communicate in English are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dupilumab treatment for 12 weeks with weekly subcutaneous injections
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Dupilumab
Dupilumab is already approved in United States, European Union for the following indications:
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ann & Robert H Lurie Children's Hospital of Chicago
Lead Sponsor
Northwestern University
Lead Sponsor
Regeneron Pharmaceuticals
Industry Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School